Download now: Gold and Silver Mining Stocks

Biotech Firm Develops Cancer Antibody

Granted Licensing Agreement

Written by Swagato Chakravorty
Posted September 4, 2012 at 3:13PM

Danish biotech firm Genmab A/S (CPH: GEN) has reached a worldwide licensing and development arrangement with Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Biotech Inc. for daratumumab (HuMax-CD38).

Daratumumab, a human CD38 monoclonal antibody with wide-ranging killing activity, is presently in Phase I/II trials in relapsed, refractory multiple myeloma. It targets the CD38 molecule, which is typically highly expressed on the surface of MM cells. It may also find application in the case of other tumors where CD38 is prominently expressed.

The agreement will see Genmab grant Janssen an exclusive global license to develop and market both daratumumab and a backup human CD38 antibody.

From the Sacramento Bee:

"Janssen was one of the first companies to recognize the power and promise of monoclonal antibodies and today is a world leader in biologics. We look forward to applying that same expertise to daratumumab to help meet the needs of patients with multiple myeloma," said William N. Hait, M.D., Ph.D., head of Janssen Research & Development, LLC. "Daratumumab is an exciting, innovative compound, and we are delighted to add it to our portfolio."

Janssen has already made a payment, and it will continue making payments in time with specified development and other milestones. Genmab will shoulder the responsibility of successfully completing GEN501 and GEN503 Phase I/II trials, while Janssen will handle all other activities. Johnson & Johnson, linked to Janssen, will be making an equity investment in Genmab.

The Janssen Pharmaceutical Companies of Johnson & Johnson works in researching oncology, immunology, neuroscience, infectious disease, and cardio/metabolic diseases. The company works to develop integrated healthcare solutions alongside healthcare stakeholders.

Genmab is publicly traded, and it is a global biotechnology company which specializes in creating and developing differentiated human antibodies for cancer treatment.



Related Articles

2012 ASCO Conference Stocks
Analyst Ian Cooper takes a look at some of the top presenters at this year's 2012 ASCO conference and offers a few ways to trade the event.
Biotech Investments Prosper from Takeovers
The acquisition of Human Genome Sciences has sparked interest in potential biotech takeovers plays.
New Jersey Biotech Companies
New Jersey has reported a profitable two years in the biotech sector despite economic shortcomings.


What is the benefit of the email subscription?
While the Wealth Daily website offers access to the articles and reports, as a newsletter subscriber you will be among the first to receive access to the valuable advice, delivered directly to your inbox daily, and you will have access to deals on our exclusive services.
Greece's Keynesian Experiment
Big Government Doesn't Work
China's World Domination
And Why it's Not Going to Happen
Should Greece Pay Its Debt?
The Case for a Greek Default
Gold's Early Warning
Deflation May Be Coming
There's No Escaping Austrian Economics
Fed Bubble is Popping
Guaranteed Returns in Cotton Futures!
Uncle Sam's $5 Billion Cotton Scam
Investing in Rhenium
More Valuable Than Oil and Gold Combined!
Greece is Screwed!
10 Ways to Protect Yourself from the Global Economic Crisis
Investing in the Next Silver Bull Market
Silver Short Selling: Manipulation or Opportunity?
The Best Reason to Buy Silver
A Long-term Outlook for Silver